Where are you?
  • Austria
  • Belgium
  • Denmark
  • Finland
  • France
  • Germany
  • Guernsey
  • Ireland
  • Italy
  • Jersey
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Singapore
  • Sweden
  • Switzerland
  • United Kingdom
  • Rest of World
It looks like you’re in
Not your location?
And finally, please confirm the following details
I’m {role} in {country} and I agree to comply with the terms of the website.

Liontrust UK Micro Cap Fund

June 2021 review

Past performance is not a guide to future performance. Do remember that the value of an investment and the income generated from them can fall as well as rise.

The Liontrust UK Micro Cap Fund returned 4.3%* in June. The FTSE Small Cap (excluding investment trusts) Index and the FTSE AIM All-Share Index comparator benchmarks returned 0.9% and -0.5% respectively. The average return of funds in the IA UK Smaller Companies sector, also a comparator benchmark, was 0.5%.


The UK equity market added modestly to this year’s strong gains as investors waited to see whether the inflationary forces emerging from the economic recovery are likely to prompt any action from central banks. Uncertainty on the public health front also remains, with much debate over the interaction of the spread of new Covid-19 strains such as the delta variant with the planned removal of social restrictions.


In portfolio news, shares in Avingtrans (+28%) rose through June, helped by the announcement of an extended contract with Sellafield’s nuclear decommissioning body. Avingtrans designs, manufactures and supplies critical components and services to the energy, medical and industrial sectors. Sellafield exercised the option to move into the second phase of its contract with Avingtrans’ Stainless Metalcraft unit, adding an extra £20m to the contract won in 2015 (and now worth £70m in total). It will produce around 1,000 boxes used to store waste retrieved from legacy locations in Cumbria, contributing to the effort to reduce the nuclear hazard at Sellafield.


Semiconductor designer and manufacturer CML Microsystems (+25%) released full-year results showing falls in sales and profits due to the pandemic, but also including upbeat outlook comments. During the year it announced the sale of its Hyperstone storage division, leaving it focused solely on the communications market. The US$49m deal bolstered its balance sheet during a tough year in which semiconductor demand from voice-centric radio manufacturers dropped substantially. Overall, revenues fell 17% to £12.5m in the year to 31 March, while at the pre-tax level it broke even versus a £1.2m profit last year. It expects activity levels to improve, aided by a record order book and a recovery from its customers, many of whom CML believes are currently holding reduced inventory levels.


Although full-year results to 31 March confirmed an 18% revenue drop for Mind Gym (+30%), they also showed rapidly improving momentum as the year progressed, as shown by its revenue growth each quarter: -40% year-on-year in Q1; -38% in Q2; -2% in Q3; and +15% in Q4. The corporate training business doubled its digitally enabled revenues, which now account for almost 80% of the total. Mind Gym has experienced a strong start to the new year and expects revenues in the 12 months to 31 March 2022 to at least recover their pre-Covid levels. It will continue investing in its digital products, meaning that it expects only to break even this year, with a return to profitability expected the following year.


For some of the portfolio’s detractors, the direction of their share price in June didn’t reflect the tone of stockmarket updates during the month. K3 Capital Group (-6.8%) is a good example; the company sales specialist commented that earnings in the year to 31 May would be ahead of both its most recent guidance and consensus market expectations. However, with the shares having already risen 50% in 2021, they succumbed to some profit-taking. Yourgene Health (-11%) slid despite notifying the market of some new contract wins, while Inspiration Healthcare Group (-8.5%) fell in the first half of the month without obvious cause, before rallying after hosting a capital markets day.


Positive contributors included:

Mind Gym (+30%), Avingtrans (+28%), Inspired Energy (+26%), CML Microsystems (+25%) and Cerillion (+17%).


Negative contributors included:

Yourgene Health (-11%), Inspiration Healthcare Group (-8.5%), K3 Capital Group (-6.8%), Fonix Mobile (-6.0%) and Cohort (-5.7%).


Discrete years' performance** (%), to previous quarter-end:







Liontrust UK Micro Cap I Acc






FTSE Small Cap ex ITs






FTSE AIM All Share






IA UK Smaller Companies













*Source: Financial Express, as at 30.06.21, total return (net of fees and income reinvested), bid-to-bid, institutional class. Non fund-related return data sourced from Bloomberg.


**Source: Financial Express, as at 30.06.21, total return (net of fees and income reinvested), bid-to-bid, institutional class.

Understand common financial words and terms See our glossary
Key Risks 
Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested. The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.
Some of the Funds managed by the Economic Advantage team invest primarily in smaller companies and companies traded on the Alternative Investment Market.  These stocks may be less liquid and the price swings greater than those in, for example, larger companies. 


This is a marketing communication. Before making an investment, you should read the relevant Prospectus and the Key Investor Information Document (KIID), which provide full product details including investment charges and risks. These documents can be obtained, free of charge, from www.liontrust.co.uk or direct from Liontrust. Always research your own investments. If you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances. 
This should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust. Always research your own investments and if you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances. 

Related commentaries

See all related

How to invest in Liontrust funds

Through a fund platform
Through a financial adviser
Direct with Liontrust